• Explore /
  • Poster
  • / Health-related quality of life (HrQoL) of first-line treatments in metastatic renal cell carcinoma (mRCC): A network meta-analysis.

Health-related quality of life (HrQoL) of first-line treatments in metastatic renal cell carcinoma (mRCC): A network meta-analysis.

Abstract Poster

Authors

null

Oluseyi Abidoye

Mayo Clinic Arizona, Phoenix, AZ

Oluseyi Abidoye , Syed Arsalan Ahmed Naqvi , Kunwer Sufyan Faisal , Manal Imran , Kaneez Zahra Rubab Khakwani , Ammad Raina , Nikita Tripathi , Haidar Abdul-Muhsin , Brian Addis Costello , Parminder Singh , Alan Haruo Bryce , Irbaz Bin Riaz

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Renal Cell Cancer; Adrenal, Penile, and Testicular Cancers

Track

Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer

Sub Track

Symptoms, Toxicities, Patient-Reported Outcomes, and Whole-Person Care

Citation

J Clin Oncol 42, 2024 (suppl 4; abstr 412)

DOI

10.1200/JCO.2024.42.4_suppl.412

Abstract #

412

Poster Bd #

G15

Abstract Disclosures

Similar Posters

First Author: Yu Fujiwara

First Author: Rabbia Siddiqi

First Author: David Cella

Poster

2024 ASCO Genitourinary Cancers Symposium

Combination nivolumab and ipilimumab with and without camu camu in first-line treatment of metastatic renal cell carcinoma (mRCC).

Combination nivolumab and ipilimumab with and without camu camu in first-line treatment of metastatic renal cell carcinoma (mRCC).

First Author: Regina Barragan-Carrillo